Trial Profile
Proof of Concept Study of Eurartesim in Patients With Imported Uncomplicated Plasmodium Vivax Malaria
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 12 Apr 2022
Price :
$35
*
At a glance
- Drugs Dihydroartemisinin/piperaquine (Primary)
- Indications Vivax malaria
- Focus Proof of concept; Therapeutic Use
- Sponsors Alfasigma; sigma-tau SpA
- 13 Jun 2017 Status changed from recruiting to discontinued due to low recruitment.
- 03 May 2017 This trial has been discontinued in Germany (end date: 31 Dec 2016).
- 05 Apr 2017 This trial was discontinued in Italy, according to European Clinical Trials Database.